# US 2022/0031907 A1 · Stable compositions composed of a radiopaque agent and cyanoacrylate monomer and applications thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031907 A1
- Document ID: US20220031907A1
- Status: Published application
- Kind: A1
- Application number: 17/274,927
- Filed: 2019-09-09
- Published: 2022-02-03
- Earliest claimed: 2018-09-17
- Assignees: Chemence Medical, Inc.
- Applicants: Chemence Medical, Inc.
- Inventors: David KIM; Laura BASSAM; Stephen HYNES; Kenneth BROADLEY
- Web page: https://patentgrep.com/patent/US20220031907A1

## CPC

- A61L 24/001: {Use of materials characterised by their function or physical properties}
- A61K 6/30: Compositions for temporarily or permanently fixing teeth or palates, e.g. primers for dental adhesives
- A61K 49/0447: {Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound}
- A61L 24/06: obtained by reactions only involving carbon-to-carbon unsaturated bonds {(A61L24/043, A61L24/046 take precedence)}
- A61L 2300/202: with halogen atoms, e.g. triclosan, povidone-iodine
- A61L 2300/802: Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
- A61L 2400/06: Flowable or injectable implant compositions
- A61L 2430/36: for embolization or occlusion, e.g. vaso-occlusive compositions or devices
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Described herein are compositions composed of a radiopaque agent and a cyanoacrylate monomer. These compositions cure in situ when administered to a subject and, thus, have numerous biomedical applications. The presence of the radiopaque agent allows the practitioner to visualize the compositions during and immediately after administration to the subject. The compositions are non-toxic and shelf-stable, and can be sterilized to prevent microbial growth. The compositions can be pre-mixed prior to sale and distribution, reducing the need for special training in their use.

## Claims

### Claim 1

A composition comprising a cyanoacrylate monomer and a radiopaque agent comprising at least one group comprising the structure I
wherein R1 is an alkyl group, an aralkyl group, an iodo-substituted alkyl group, an iodo-substituted aralkyl group, an iodo-substituted aryl group, or a carboxyalkyl group.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the radiopaque agent comprises two groups comprising the structure I.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the radiopaque agent has the structure II
wherein R1 is an alkyl group, an aralkyl group, an iodo-substituted alkyl group, an iodo-substituted aralkyl group, an iodo-substituted aryl group, or a carboxyalkyl group.

### Claim 4 (depends on 3)

The composition of claim 3, wherein R1 and R2 are the same alkyl group.

### Claim 5 (depends on 4)

The composition of claim 4, wherein R1 and R2 are each a C1 to C18 alkyl group.

### Claim 6 (depends on 4)

The composition of claim 4, wherein R1 and R2 are each methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, or octyl.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the cyanoacrylate monomer is an alkyl cyanoacrylate monomer, a cycloalkyl cyanoacrylate monomer, an allyl cyanoacrylate monomer, an aryl cyanoacrylate monomer, an aralkyl cyanoacrylate monomer, a carboxy alkyl cyanoacrylate monomer or an iodo-substituted cyanoacrylate monomer.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the cyanoacrylate monomer is a C1-C18 alkyl cyanoacrylate monomer.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the alkyl cyanoacrylate monomer is butyl cyanoacrylate monomer.

### Claim 10 (depends on 3)

The composition of claim 3, wherein the cyanoacrylate monomer is butyl cyanoacrylate monomer and R1 and R2 are the same alkyl group.

### Claim 11 (depends on 10)

The composition of claim 10, wherein R1 and R2 are each methyl, ethyl, propyl, butyl, pentyl, heptyl, or octyl.

### Claim 12 (depends on 1)

The composition of claim 1, wherein the cyanoacrylate monomer is from 30 wt % to 90 wt % of the composition.

### Claim 13 (depends on 1)

The composition of claim 1, wherein the radiopaque agent is from 5 wt % to 40 wt % of the composition.

### Claim 14 (depends on 1)

The composition of claim 1, wherein the composition further comprises a viscosity modifier.

### Claim 15 (depends on 14)

The composition of claim 14, wherein the viscosity modifier comprises ethyl myristate, ethyl stearate, ethyl oleate, tri-butyl citrate (TBC), tri-butyl-O-acetyl citrate (TBAC), dibutyl sebacate, a polycaprolactone, a polyglycolide, a polylactide, a polyethylene glycol ether, polyvinylacetate, or any combination thereof.

### Claim 16 (depends on 14)

The composition of claim 14, wherein the viscosity modifier is less than 50 wt % of the composition.

### Claim 17 (depends on 1)

The composition of claim 1, wherein the composition further comprises a cure speed modifier.

### Claim 18 (depends on 17)

The composition of claim 17, wherein the cure speed modifier comprises sulfur dioxide, a sulfonic acid, sulfuric acid, sulfur trioxide, a phosphorous acid, a carboxylic acid, picric acid, boron trifluoride, a BF3-ether complex, BF3.H2O, hydrofluoric acid, tin (IV) chloride, iron (III) chloride, nitrogen oxide, boron oxide, phosphoric acid, benzoic acid, cyanoacetic acid, trifluoroacetic acid, tribromoacetic acid, trichloroacetic acid, perchloric acid, hydrochloric acid, hydrobromic acid, fluorosulfonic acid, chlorosulfonic acid, toluenesulfonic acid, BH3, BCl3, BBr3, AlH3, AlCl3, Al(CH3)3, B(CH3)3, Be(CH3)2, formic acid, acetic acid, propionic acid, butyric acid, valeric acid, caproic acid, enanthic acid, caprylic acid, pelargonic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, palmitoleic acid, oleic acid, linoleic acid, linolenic acid, arachidonic acid, glyoxylic acid, glycolic acid, acrylic acid, propiolic acid, malonic acid, tartronic acid, mesoxalic acid, dihydroxymalonic acid, lactic acid, hydracrylic acid, glyceric acid, glycidic acid, isobutyric acid, acetoacetic acid, fumaric acid, maleic acid, oxaloacetic acid, tartric acid, crotonic acid, adipic acid, citric acid, aconitic acid, isocitric acid, sorbic acid, benzoic acid, salicylic acid, a crown ether, a podand, a polyalkylene oxide, a calixarene, or any combination thereof.

### Claim 19 (depends on 17)

The composition of claim 17, wherein the cure speed modifier comprises acetic acid or citric acid.

### Claim 20 (depends on 17)

The composition of claim 17, wherein the cure speed modifier is less than 15,000 ppm of the composition.

### Claim 21

A composition produced by admixing a cyanoacrylate monomer and a radiopaque agent and a radiopaque agent comprising at least one group comprising the structure I
wherein R1 is an alkyl group, an aralkyl group, an iodo-substituted alkyl group, an iodo-substituted aralkyl group, an iodo-substituted aryl group, or a carboxyalkyl group.

### Claim 22 (depends on 1)

The composition of claim 1, wherein the composition has a viscosity of from 1 cP to 5,000 cP.

### Claim 23 (depends on 1)

The composition of claim 1, wherein the composition is sterilized.

### Claim 24 (depends on 1)

A method for reducing or inhibiting blood flow in a blood vessel of a subject comprising introducing into the vessel the composition of claim 1, wherein the composition creates an artificial embolus within the vessel.

### Claim 25 (depends on 24)

The method of claim 24, wherein the method reduces or inhibits blood flow to a tumor, an aneurysm, a varicose vein, an arteriovenous malformation, or a bleeding wound.

### Claim 26 (depends on 1)

A method for reinforcing the inner wall of a blood vessel in a subject comprising introducing into the vessel the composition of claim 1.

### Claim 27 (depends on 1)

A method for closing or sealing a puncture in a blood vessel in a subject comprising applying to the puncture the composition of claim 1.

### Claim 28 (depends on 1)

A method for repairing a bone fracture in a subject comprising contacting the fractured bone with the composition of claim 1.

### Claim 29 (depends on 1)

A method for adhering a substrate to a bone of a subject comprising (1) contacting the bone and/or substrate with the composition of claim 1 and (2) applying the substrate to the bone to adhere the substrate to the bone.

### Claim 30 (depends on 1)

A method for adhering a bone-tissue scaffold to a bone of a subject comprising contacting the bone and/or bone-tissue scaffold with the composition of claim 1 and (2) applying the bone-tissue scaffold to the bone to adhere the bone-tissue scaffold to the bone.

### Claim 31 (depends on 1)

A method for bonding a soft tissue scaffold to soft tissue or two soft tissue scaffolds or two soft tissues comprising (1) applying to the tissue scaffolds and/or soft tissues the composition of claim 1 and (2) contacting the soft tissue scaffold to soft tissue, the two soft tissue scaffolds or the two soft tissues.

### Claim 32 (depends on 1)

A method for treating a wound within the subject comprising applying to the wound the composition of claim 1.

### Claim 33 (depends on 1)

A method for closing or sealing a puncture in internal tissue or membrane comprising (1) applying the composition of claim 1 to a patch and/or the puncture and (2) adhering the patch to the puncture.

### Claim 34 (depends on 1)

A method for filling a tissue void in a subject comprising introducing into the void the composition of claim 1.

### Claim 35 (depends on 1)

A method for sealing a fistula in a subject, the method comprising contacting or filling the fistula with the composition of claim 1.

### Claim 36 (depends on 1)

A method for preventing or reducing the adhesion of two tissues in a subject comprising contacting at least one surface of the tissue with the composition of claim 1.

### Claim 37 (depends on 1)

A method for sealing breaks or cracks in teeth comprising contacting the breaks or cracks with the composition of claim 1.

### Claim 38 (depends on 1)

A method for securing crowns or dental implants comprising (1) contacting the crown with the composition of claim 1, and (2) placing the crown or dental implant in the mouth of a subject.

### Claim 39 (depends on 1)

The composition of claim 1, further comprising one or more bioactive agents.

### Claim 40 (depends on 39)

The composition of claim 39, wherein the one or more bioactive agents comprise an antibiotics, a pain reliever, an immune modulator, a growth factor, an enzyme inhibitor, a hormone, a mediator, a messenger molecule, cell a signaling molecule, a receptor agonist, an oncolytic, a chemotherapy agent, a receptor antagonist, or a combination thereof.
